Table 2.
Prevalence of SPAs Among Surgically Resected Pituitary Tumors
| Histologic Type | Percentage of All Pituitary Tumors (IHC for Pituitary Hormones) | Percentage of All Pituitary Tumors (IHC for Pituitary Hormones and Transcription Factors) | Percentage of Silent Tumors Within Histologic Subtype (IHC for Pituitary Hormones) | Percentage of Silent Tumors Within Histologic Subtype (IHC for Pituitary Hormones and Transcription Factors) | Difference in Invasiveness and Recurrence Compared With Silent Gonadotroph Adenomas |
|---|---|---|---|---|---|
| Gonadotroph | 28.2 | 35.6 | 99.3 | 99.5 | Not applicable |
| Null cell adenoma | 11.1 | 0.6 | 100 | 100 | More invasive; greater surgical reintervention rates |
| GH/PRL/TSH lineage | 46.2 | 48.4 | 9.2 | 9.7 | Larger tumor size |
| Greater recurrence rates | |||||
| Corticotroph | 14.5 | 17.5 | 32.9 | 44.4 | Frequently giant adenomas; marked cavernous sinus invasion; greater recurrence rates |
Derived from data from Nishioka H, Inoshita N, Mete O, et al. The complementary role of transcription factors in the accurate diagnosis of clinically nonfunctioning pituitary adenomas. Endocr Pathol 2015; 26:349-355.